FDA Drug User Free Act: adding "comparative effectiveness" tests will not help consumers

FOR IMMEDIATE PRESS RELEASE: June 16, 2011

In a just released AEI Health Policy Outlook, AEI scholar Scott Gottlieb, M.D. argues that adding a new mandatory "comparative effectiveness" test to the approval process for new drugs in the reauthorization of the Food and Drug Administration (FDA) Prescription Drug User Fee Act constitutes a needless waste of time and money.
Among the key points:

  • Consumer groups are pushing to add a step to the FDA drug approval process: "comparator" trials, which test a new drug against the current standard treatment.
  • But these trials are already being conducted where it really matters. A new FDA approval requirement would unnecessarily slow down the approval process for all other drugs.
  • Achieving the goal consumer groups want--safer and more cost-effective drugs--requires innovation in clinical trial design, not a congressional mandate.

Scott Gottlieb is available for interviews and can be reached at [email protected] or through his assistant [email protected]

(202.862.7183).

 

Also Visit
AEIdeas Blog The American Magazine

What's new on AEI

We still don't know how many people Obamacare enrolled
image The war on invisible poverty
image Cutting fat from the budget
image Speaker of the House John Boehner on resetting America’s economic foundation
AEI on Facebook
Events Calendar
  • 22
    MON
  • 23
    TUE
  • 24
    WED
  • 25
    THU
  • 26
    FRI
Monday, September 22, 2014 | 2:30 p.m. – 4:00 p.m.
Policy implications of the new US labor market normal

We welcome you to join us as a panel of economists discuss US wage and price prospects in the coming months and the implications for the Federal Reserve’s current unorthodox monetary policy.

No events scheduled today.
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.
No events scheduled this day.